Literature DB >> 3038564

Internalization of human T lymphocyte receptors.

A Telerman, R B Amson, F Romasco, J Wybran, P Galand, R Mosselmans.   

Abstract

Monoclonal antibodies specific to human T lymphocyte receptors are currently being used to define the biochemical structure of these proteins as well as of functionally distinct cell subsets. Since one of the antibodies (OKT3) recognizing the T3 (CD3) receptor mimics vital physiological processes involved in the activation of the immune system and has been successfully used as a therapeutical agent, we investigated one of the mechanisms underlying this antibody-receptor interaction. Our results show that after binding of OKT3, the complex (OKT3-T3) disappears rapidly from the cell surface. Using electron microscopy, we found that this down-regulation is due to the internalization of the complex. Parallel experiments performed on the T11 (CD2) and T4 (CD4)/AIDS retrovirus receptor indicate that the same mechanism applies for the down-regulation of those molecules. These data suggest that the T3, T11 and T4 receptors have a behavior comparable to other well characterized, hormonal and viral receptors; they provide information on the metabolization pathway of surface receptors and on the possible intracellular penetration of ligands like the HTLV-III/LAV agent in human T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038564     DOI: 10.1002/eji.1830170715

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Jun NH2-terminal kinase is constitutively activated in T cells transformed by the intracellular parasite Theileria parva.

Authors:  Y Galley; G Hagens; I Glaser; W Davis; M Eichhorn; D Dobbelaere
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

2.  Activated rat T cells synthesize and express functional major histocompatibility class II antigens.

Authors:  C P Broeren; M H Wauben; M A Lucassen; M Van Meurs; P J Van Kooten; C J Boog; E Claassen; W Van Eden
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

3.  Src-like adaptor protein down-regulates T cell receptor (TCR)-CD3 expression by targeting TCRzeta for degradation.

Authors:  Margaret D Myers; Leonard L Dragone; Arthur Weiss
Journal:  J Cell Biol       Date:  2005-07-18       Impact factor: 10.539

Review 4.  Endocytic events in TCR signaling: focus on adapters in microclusters.

Authors:  Lakshmi Balagopalan; Valarie A Barr; Lawrence E Samelson
Journal:  Immunol Rev       Date:  2009-11       Impact factor: 12.988

5.  Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness.

Authors:  R B Landewé; A M Miltenburg; M J Verdonk; C L Verweij; F C Breedveld; M R Daha; B A Dijkmans
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

6.  Localization of lysosomal antigens in activated T-lymphocytes.

Authors:  G Bou-Gharios; J Moss; I Olsen
Journal:  Histochem J       Date:  1991-10

7.  CD3 gamma contains a phosphoserine-dependent di-leucine motif involved in down-regulation of the T cell receptor.

Authors:  J Dietrich; X Hou; A M Wegener; C Geisler
Journal:  EMBO J       Date:  1994-05-01       Impact factor: 11.598

8.  Requirements for peptide-induced T cell receptor downregulation on naive CD8+ T cells.

Authors:  Z Cai; H Kishimoto; A Brunmark; M R Jackson; P A Peterson; J Sprent
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

9.  The intersectin 2 adaptor links Wiskott Aldrich Syndrome protein (WASp)-mediated actin polymerization to T cell antigen receptor endocytosis.

Authors:  M K McGavin; K Badour; L A Hardy; T J Kubiseski; J Zhang; K A Siminovitch
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

10.  T cell receptor engagement leads to phosphorylation of clathrin heavy chain during receptor internalization.

Authors:  Victoria L Crotzer; Allan S Mabardy; Arthur Weiss; Frances M Brodsky
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.